Gilead Sciences stock (US3755581036): Analyst upgrade and steady Q1 2026 revenue keep focus on HIV and oncology

Gilead Sciences has moved back into the spotlight after Maxim Group upgraded the Nasdaq-listed biopharma stock to “buy” with a price target of $165, only weeks after the company reported first-quarter 2026 revenue of about $6.96 billion and robust profitability, according to MarketBeat as of 05/20/2026 and summary financial data compiled by Invezz as of 05/2026.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

Gilead Sciences: core business model

Gilead Sciences is a large US-based biopharmaceutical company focused on developing and commercializing therapies in infectious diseases and oncology. The group became widely known for its antiviral medicines targeting HIV and hepatitis C, which have generated substantial cash flows over the past decade, according to the company’s corporate information on Gilead’s website as of 2026. Over time, Gilead has used these cash flows to invest in research, clinical development and strategic deals.

The business model combines internally discovered drugs with assets gained through acquisitions and partnerships. Gilead typically invests heavily in late-stage clinical programs and then seeks to scale approved products globally by working with healthcare systems, payers and distributors, especially in the United States, Europe and key emerging markets. This approach allows the company to build franchises around specific disease areas, targeting large patient populations where unmet medical needs remain significant.

In recent years, Gilead has focused on diversifying beyond its original antiviral concentrations. The company has moved deeper into oncology and inflammation through targeted therapies and cell-based treatments, including CAR-T products, aiming to establish new long-term growth pillars. These newer areas require significant upfront R&D and commercialization spending but could extend the company’s growth trajectory as older products face pricing pressure and competition.

Main revenue and product drivers for Gilead Sciences

Gilead’s largest revenue contributor remains its HIV franchise, which is described as a strong cash generator with around 10% year-on-year growth in the first quarter of 2026, according to an overview of recent performance cited by Simply Wall St as of 05/2026. The company markets a portfolio of combination therapies and preventive treatments that are widely used in the US and other developed markets. High adherence, broad reimbursement and ongoing medical need help underpin this segment.

Beyond HIV, Gilead generates meaningful revenue from treatments for viral hepatitis and other infectious diseases. However, some of these markets, such as hepatitis C, have matured as curative regimens reduce the pool of treatable patients. This dynamic has pushed Gilead to invest more aggressively in oncology and inflammatory diseases, where it sees room for innovation and long-term indications. The company’s oncology efforts include targeted therapies and immuno-oncology approaches that could address both blood cancers and solid tumors if clinical data remain supportive.

The mix of stable cash flows from established antivirals and growth investments in oncology and inflammation shapes Gilead’s financial profile. According to highlights from a recent earnings call, the company reported product gross margin of roughly 87% and operating margin around 47% for a recent quarter, underlining the profitability of its portfolio even while it invests in new assets, as summarized by TipRanks as of 05/2026. These margins provide scope to fund pipeline programs, business development and shareholder returns.

Recent earnings: Q1 2026 revenue and profitability

For the first quarter of 2026, Gilead Sciences reported revenue of about $6.96 billion, slightly above the $6.67 billion recorded in the same quarter a year earlier, according to quarterly line items compiled by Invezz as of 05/2026. This implies low single-digit percentage growth year on year, reflecting contributions from the HIV portfolio and newer medicines, partly offset by headwinds in some legacy areas. Gross profit for the quarter was reported at roughly $5.52 billion, indicating high gross margins typical for branded specialty pharmaceuticals.

MarketBeat, citing the company’s quarterly figures, noted that Gilead generated a return on equity of about 48% and a net margin close to 31% for the recent quarter, underlining the efficiency with which the company converts its revenue base into bottom-line results, according to MarketBeat as of 05/20/2026. While these figures can fluctuate due to one-time items, they illustrate the earnings power of Gilead’s core franchises.

Commentary from earnings-related coverage emphasizes that profitability has remained robust despite heavy investment. An overview of the recent earnings call highlighted that product gross margin reached about 87% and operating margin around 47%, even as Gilead continues to allocate substantial resources to R&D and deal-related expenses, according to TipRanks as of 05/2026. This combination of high margins and ongoing investment is central to how the company positions itself for future growth.

Analyst actions: Maxim Group upgrade and other views

On May 20, 2026, Maxim Group upgraded its view on Gilead Sciences from “hold” to “buy” and set a price target of $165 per share, according to a research summary reported by MarketBeat as of 05/20/2026. The report noted that shares of Gilead opened at about $130.50 on the day of the upgrade and that the company’s latest quarterly revenue was roughly $6.96 billion, reinforcing the link between operational performance and analyst sentiment.

The same MarketBeat summary indicated that, at the time of publication, a large majority of analysts covering Gilead rated the stock as a form of “buy,” with a smaller group assigning “hold” ratings. It also mentioned an average consensus target price of around $156.93, illustrating how Wall Street expectations cluster above the current trading level while still spanning a range of views. These targets and ratings are subject to change as new clinical data, competitive developments or regulatory decisions emerge.

In parallel, other investment banks have been revisiting their models after Gilead’s recent results. On May 10, 2026, Morgan Stanley reduced its price target on Gilead from $175 to $168 while maintaining an “overweight” stance, reflecting a more cautious view on some assumptions but ongoing confidence in the broader investment case, according to a report summary cited by Insider Monkey as of 05/2026. Together, these moves show that analysts are actively recalibrating expectations in light of new information.

Valuation perspectives and premium to intrinsic estimates

Alongside bank research, valuation-focused platforms have commented on how Gilead trades relative to their internal fair value metrics. GuruFocus reported that, based on its proprietary GF Value model, Gilead had an estimated intrinsic value of about $95.66 per share at a recent date, while the stock was trading at a premium of roughly 36% to that level, according to GuruFocus as of 05/2026. From that perspective, the shares would appear overvalued versus this specific measure, although such models depend heavily on assumptions.

GuruFocus also noted the Maxim Group upgrade and the $165 price target as part of its commentary, pointing out that sell-side analysts see upside relative to the then-current trading price, even if some quantitative models flag a premium to historical valuation norms. For investors, this creates a nuanced picture: traditional valuation screens may suggest caution, while analysts highlighting pipeline potential and cash generation focus more on medium-term growth dynamics.

It is important to recognize that no single valuation framework captures all the factors at play for a research-driven biopharma company. Elements such as clinical trial readouts, patent cliffs, pricing negotiations and regulatory changes can shift outlooks quickly and are not always fully reflected in backward-looking metrics. As a result, US investors often compare multiple perspectives, from discounted cash flow assumptions to relative multiples and specialized tools like the GF Value metric.

Industry trends and competitive position

Gilead operates in a highly competitive global biopharmaceutical landscape, where large-cap companies vie to bring differentiated therapies to market. In HIV, Gilead faces competition from other multinational drug makers, but it has managed to maintain a leading position through a broad portfolio of products and continuing innovation in treatment regimens, according to sector overviews referenced by Simply Wall St as of 05/2026. Long-acting formulations and preventive approaches remain areas of industry focus.

In oncology, Gilead is competing in a crowded and fast-moving field that includes targeted therapies, immunotherapies and cell-based treatments. While the company entered this area later than some peers, it has sought to close the gap through acquisitions and collaborations, particularly in blood cancers and inflammation-related pathways. The pipeline’s eventual commercial success will depend on clinical outcomes, regulatory approvals and differentiation against existing standards of care.

Broader industry trends, including pricing scrutiny in the US and evolving reimbursement models, also influence Gilead’s operating environment. Policymakers and payers have been examining ways to control drug spending, which could pressure pricing or require value-based arrangements in some indications. For a company like Gilead, which generates a significant portion of revenue in the US market, these developments are closely watched, even as innovation can support continued demand for high-impact therapies.

Why Gilead Sciences matters for US investors

For US-based investors, Gilead Sciences is a prominent component of the domestic biopharma sector, listed on Nasdaq under the ticker GILD and included in several major healthcare and broad-market indexes. The company’s large market capitalization, active trading volume and regular analyst coverage make it a commonly followed name among institutional and retail investors. Its performance can influence sector sentiment, particularly in the field of infectious disease and oncology-focused drug makers.

Gilead’s exposure to the US healthcare system is substantial, as a significant proportion of its revenue is generated from US patients and payers. This means that changes in US policy, reimbursement practices and competitive dynamics can have a direct impact on the company’s earnings profile. For investors tracking the intersection of healthcare reforms, innovation and market access, Gilead offers a case study in how large-cap biopharma groups navigate these forces while funding extensive R&D pipelines.

In addition, Gilead’s cash generation and balance sheet flexibility often enable it to pursue share repurchases, dividends or strategic transactions, depending on management’s capital allocation priorities. While specific decisions vary over time and are subject to board approval, the company’s underlying cash flow from the HIV and antiviral franchises provides latitude for multiple uses of capital. This can be relevant for US investors who consider both growth potential and income elements when assessing large healthcare holdings.

Conclusion

Gilead Sciences continues to balance the strengths of its established HIV and antiviral franchises with significant investment in oncology and inflammatory diseases, as reflected in its Q1 2026 revenue of about $6.96 billion and high margins. Recent analyst actions, including Maxim Group’s upgrade to “buy” with a $165 target and Morgan Stanley’s updated “overweight” view, highlight how Wall Street is weighing robust cash generation against valuation considerations and pipeline execution risk. For US investors watching the healthcare sector, Gilead remains a large, profitable biopharma player whose future trajectory will depend on sustaining its core portfolio while successfully converting its research and deal activity into durable new revenue streams.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

en | US3755581036 | GILEAD SCIENCES | boerse | 69383514 | bgmi